DEGREE (if applicable)

Transcription

1 OMB No (Rev. 09/17 Approved Through 03/31/2020) BIOGRAPHICAL SKETCH Provide the following information for the Senior/key personnel and other significant contributors. Follow this format for each person. DO NOT EXCEED FIVE PAGES. NAME: Grace L. Su era COMMONS USER NAME (credential, e.g., agency login): POSITION TITLE: Associate Chief of Medicine, Specialty Care and Access EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.) INSTITUTION AND LOCATION DEGREE (if applicable) Completion Date MM/YYYY FIELD OF STUDY Yale University, New Haven, CT B.S. 05/1984 Biology University of Chicago, Chicago, IL M.D. 06/1988 Medicine University of Pittsburgh, Pittsburgh, PA 06/1991 Internal Medicine University of Pittsburgh, Pittsburgh, PA 06/1994 Gastroenterology and Hepatology A. Personal Statement I am a physician scientist and hepatologist who has dedicated her career to the development of better care for patients with liver disease. As the Associate Chief of Medicine, Specialty Care and Access, and director of the VA SCAN-ECHO program at the VA Ann Arbor Healthcare System, I am acutely aware of the need for efficient access to specialty care, particularly for rural and underserved Veterans. My research interest in analytic moprhomics, an innovative high-throughput, anatomically indexed methodology for assessing body composition and organ measurements from the data files of CT scans offers an unique opportunity to provide risk assessment in patients with liver disease which can be leveraged for developing novel approaches to specialty consultation. As the single largest medical system in the United States with one of the oldest integrated electronic medical record system and networked storage of radiological imaging, the VA provides a powerful and unique environment for this research proposal. As a Professor of Medicine at the University of Michigan and associate director of the Morphomics Analysis Group, I have had the privilege of working with a multidisciplinary group of scientists from multiple medical specialties and engineers to develop novel applications of analytic morphomics to clinical diseases. I believe that my expertise in translational medicine and in the area of developing analytic morphomic tools makes me ideally qualified to carry out the technical aspects of this proposal relating to this unique technology. To implement this from a health services and research perspective, I am eager to work closely with my -PD/PI, Dr. Sameer Saini, who has extensive experience in health services research. I have worked collaboratively with Sameer for nearly 15 years on ongoing federally-funded research, co-mentoring of trainees and early career faculty, and programmatic initiatives. We plan to meet on a weekly basis during the study period, and our collaboration will be facilitated by a clear delineation of our complementary roles and responsibilities, as detailed in our Multiple PD/PI Leadership Plan. 1. Mellinger JL, Moser S, Welsh DE, Yosef MT, McCurdy H, Rakoski MO, Moseley RH, Glass L, Waljee AK, Volk ML, Sales A, Su GL. Access to subspecialty care and survival among patients with liver disease. Am J Gastro 111: , PMID: Krishnamurthy V, Zhang P, Ethiraj S, Enchakalody B, Waljee AK, Wang L, Wang SC, Su GL. Utilization of Analytic Morphomics of Liver, Spleen, and Body Composition to Predict Cirrhosis. Clinical Gastroenterology and Hepatology 13: , PMID:

2 3. Zhang P, Peterson M, Ph.D, Su GL, Wang SC. Visceral adiposity is negatively associated with bone density and muscle attenuation. Am J Clin Nutrition 101: , 2015 PMCID: PMC Tapper EB, Parikh N, Sengupta N, Mellinger J, Ratz D, Lok AS, Su GL. Predicting the Development of Hepatic Encephalopathy in a Population-Based Cohort of Patients with Cirrhosis, Hepatology (in press) B. Positions and Honors Positions and Employment: Assistant Professor, Division of Gastroenterology and Hepatology and Division of Transplantation Medicine, Department of Medicine and co-appointment in the Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA Assistant Professor, Division of Gastroenterology, Department of Medicine, University of Michigan School of Medicine, Ann Arbor, MI Associate Professor with Tenure, Division of Gastroenterology, Department of Medicine, University of Michigan School of Medicine, Ann Arbor, MI Faculty, Immunology Graduate Program, Horace Rackham School of Graduate Studies, University of Michigan, Ann Arbor, MI Staff Physician (Acting Chief: 2006) Gastroenterology Section, VA Ann Arbor Healthcare System, Ann Arbor, MI Chief, Gastroenterology Section, VA Ann Arbor Healthcare System, Ann Arbor, MI Program Director, VA Ann Arbor Healthcare Center Specialty Care Access Network-Extension of Healthcare Outcome (SCAN-ECHO), Ann Arbor, MI Professor with Tenure, Division of Gastroenterology, Department of Medicine, University of Michigan School of Medicine Professor of Surgery, University of Michigan School of Medicine, Ann Arbor, MI Associate Director, Morphomics Analysis group, University of Michigan School of Medicine Associate Chief of Medicine, Subspecialty Care and Access, VA Ann Arbor Healthcare System, Ann Arbor, MI Other Experience and Professional Memberships Gastroenterology, Special Section Editor, July 2011-June 2016 Department of Veterans Affairs National Hepatitis C-VA ECHO Curriculum Workgroup: Clinical Liver disease, Guest Editor, Volume 4, Issue 3, September 2014 Netter Collection: The Digestive System, Associate Editor, April Co-Director- VISN 11 Hepatitis C Innovation Team to 2016 VA Center for Clinical Management Research, Ann Arbor HSR&D Center of Innovation, Steering Committee: 2016 to present Honors and Awards Magna Cum Laude, Distinction in Major, Yale College, 1984; Sigma Xi Scientific Society, Yale College,1984; Alpha Omega Alpha, 1987; American Medical Women Association Award for Scholastic Achievement, 1988; University of Chicago Richard W. Reilly Award for Outstanding Aptitude in Gastroenterology, 1988; Graduation with Honors, University of Chicago Pritzker School of Medicine, 1988 ; American Gastroenterology Association Foundation Senior Fellow Research Award, 1993; Physician Scientist Award (K11), NIH, 1993; Traditions of Leadership Award, University of Michigan, 2000; Outstanding Educator Award by Graduating Fellows (2008 and 2010), NIH Immunology IRG Special Study Section, 2002; NIH GMA-3 Study Section, October, 2003; NIAAA IRG Special Study Section, 7/2005,10/2012, 9/2013, NIDDK Scientific Review Group DDK-C, 6/2003, 6/2004, 3/2005, 10/2005, 3/2006, 6/2006, 10/2012, 9/2013, and 10/2015; NIH DDK-C study section standing member Detroit Federal Executive Board s Employee of the Year Award (2010), Department of Veterans Affairs Certificate of Pride in Public Service (2010) C. Contribution to Science Development of Analytic Morphomics for the Diagnosis and Prognosis of Liver Disease Using analytic morphomics to examine body composition and organ features in patients with chronic liver disease, I have developed prediction models to assess diagnosis of cirrhosis which outperform standard laboratory based models. In addition, we have found that certain body composition features also predict outcome after liver transplantation and hepatocellular carcinoma. I was the principal investigator in these studies.

3 1. Singal AG, Zhang P, Anathakrishnan L, Parikh ND, Waljee AK, Sharma P, Barman P, Krishnamurthy V, Wang L, Wang SC, Su GL. Body composition features predicts overall survival in patients with hepatocellular carcinoma. Clin Transl Gastro 2016 May 26;7:e172. PMID: Huhdanpaa H, Douville C, Baum K, Krisnamurthy V, Holcombe S, Enchakalody B, Wang L, Wang SC, Su GL. Predictive Value of Quantitative Image Analysis of Abdominal CT Scans for the Diagnosis of Cirrhosis. Scand J. Gastro 46: , Sharma P, Parikh ND, Yu J, Barman P, Derstine BA, Sonnenday CJ, Wang SC, Su GL, Bone Mineral Density Predicts Post-transplant Survival among Hepatocellular Carcinoma Liver Transplant Recipients, Liver Transplantation 22: , Huhdanpaa HT, Peng Z, Krishnamurthy VN, Douville C, Enchakolody B, Chou C, Ethiraj S, Wang SC, Su GL. Quantitative Detection of Cirrhosis: Towards the Development of Computer Assisted Detection Method, Journal of Dig Imaging 27: , PMCID: PMC Evaluating models of care which leverage technology to provide subspecialty care to remote sites Due to the geographic clustering subspecialists in tertiary care center, access to subspecialty care is a significant problem in many parts of the United States, particularly in rural and underserved areas. To address this, problem, we were funded to implement and evaluate the SCAN-ECHO demonstration project in the VA Ann Arbor Healthcare System. The goal of this project was to create highly innovative approach towards subspecialty care which leveraged technology to virtually deliver care to remote regions. Unlike prior telemedicine initiatives, this project is directed at training primary care providers in distant locations to better care for patients with complex disease through a combination of case based distance learning and patient comanagement. In order to evaluate this program, we developed a liver disease cohort for our VISN using administrative data retrieved through the central data warehouse. By examining this large VA based dataset we found that access to subspecialty care improved mortality in patients with chronic liver disease. In addition, we found that with appropriate risk stratification, a SCAN-ECHO visit was equivalent to a face to face visit (publication submitted). I was the principal investigator for these studies. 1. Mellinger JL, Moser S, Welsh DE, Yosef MT, McCurdy H, Rakoski MO, Moseley RH, Glass L, Waljee AK, Volk ML, Sales A, Su GL. Access to subspecialty care and survival among patients with liver disease. Am J Gastro 111: , PMID: Salgia R, Mullan PB, McCurdy H, Sales AE, Moseley RH, Su GL. The Educational Impact of the Specialty Care Access Network Extension of Community Healthcare Outcomes (SCAN-ECHO) Program. Telemedicine and E-health 20: , Kirsh S, Su GL, Sales A, Jain R. Access to Outpatient Specialty Care: Solutions From an Integrated Health Care System, Am J of Med Qual 30:88-90, Glass L, Waljee AK, McCurdy H, Su GL, Sales AE. Specialty Care Access Network- Extension of Community Healthcare Outcomes Model Program for Liver Disease Improves Specialty Care Access, Dig D Sci (in press) Identifying factors which determine prognosis of patients with hepatocellular carcinoma (HCC) I have had long standing interest in understanding the factors which determine prognosis in patients with HCC. We were the earliest groups to identify non-alcoholic fatty liver disease (NAFLD) as a risk factor for the development of HCC but it is not yet clear whether body features associated with NAFLD are prognostic in patients with HCC. HCC is different from other cancers in that it develops predominantly in patients with chronic liver disease. Prognosis is dependent not only on cancer features but also on patient features such as functional status and liver function. These latter 2 features are part of the most widely accepted staging system in the Western world, the Barcelona Clinic Liver Clinic (BCLC) Staging system. Our group showed that of all the staging system tested, BCLC was the most prognostic in our population. However, despite it being a relatively good staging system, the accuracy for prognosis was still lacking. In our recent studies, we found that BCLC was not predictive of outcome in patients undergoing transarterial chemoembolization. Rather, our recent studies show that objective measurements using analytic morphomics performed better than BCLC in predicting prognosis of patients with HCC and may potentially be an useful adjunct to assess patients with HCC. I was the principal investigator of these studies. 1. Parikh ND, Zhang P,Singal AG, Derstine BA, Krishnamurthy V,Barman P,Waljee AK, Su GL. Visceral Fat Density Predicts Survival in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization, Cancer Res Treat (in press)

4 2. Sharma P, Parikh ND, Yu J, Barman P, Derstine BA, Sonnenday CJ, Wang SC, Su GL, Bone Mineral Density Predicts Post-transplant Survival among Hepatocellular Carcinoma Liver Transplant Recipients, Liver Transplantation 22: , Barman PM, Sharma P, Krishnamurthy V,Willatt J, McCurdy H, Moseley RH, Su GL, Predictors of mortality in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Dig Dis Sci Nov 59(11):2821-5, PMID: PMCID: PMC Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, Lok AS. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 41: , PMID: Assessing the role of serum biomarkers as a non-invasive method to predict liver disease outcome The gold standard for assessing liver disease is a liver biopsy which is fraught with inherent risks and sample bias. We have shown in multiple clinical circumstances that serum based markers may be used to predict presence of disease such as liver fibrosis or the presence of primary liver cancer (hepatocellular carcinoma). These non-invasive approaches are clinically relevant have evolved over time as more standard approaches for clinical care. I was a co-investigator on these studies and my laboratory provided technical support to carry out these assays. I was also a clinical lead in providing the patient population from my clinical practice for these studies. 1. Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, Lok AS. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 37: , Fontana RJ, Bonkovsky L, Naishadham D, Dienstag JL, Sterling RK, Lok ASF, Su GL, and the HALT-C Trial Group. Serum fibrosis markers decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis, Clinical Gastroenterology and Hepatology 7: PMID: PMCID: PMC Fontana RJ, Dienstag JL, Bonkovsky HL, Sterling RK, Naishadham D, Goodman ZD, Lok ASF, Wright EC, Su GL, and the HALT-C Trial Group. Serum fibrosis markers are associated with histological progression and clinical outcomes in non-responder patients with chronic hepatitis C. Gut 59: , PMCID: PMC Fontana RJ, Litman HJ, Dienstag JL, Bonkovsky HL, Su GL, Sterling RK, Lok AS for the HALT-C Trial Group. YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C. Liver International. 32(4):665-74, PMCID: PMC Developing decision support tools for Crohn s Disease to improve prediction of clinical outcomes The lack of objective, accurate, and reproducible measures of intestine-specific disease activity that accounts for changes over time is a major limitation in the management of the inflammatory bowel diseases. I have had the privilege to work with a multidisciplinary time to develop analytic morphomic image analysis tools which can predict outcome in Crohn s disease. Linking longitudinal clinical and imaging data, we are in the process of developing prediction models which can provide personalized predictions of future complications in Veterans with Crohn s disease. I am the senior investigator for these studies. 1. Stidham RW, Waljee AK, Day NM, Bergmans CL, Zahn KM, Higgins PD, Wang SC, Su GL. Body fat composition assessment using analytic morphomics predicts infectious complications following bowel resection in Crohn s disease. Inflamm Bowel Dis 21: , PMID PMC Max J, Stidham R, Su GL, Waljee AK. Selected Summary: Obesity and IBD: Are We Tipping The Scales Toward and Epidemic? Gastroenterology. 145: 478-9, PMCID: PMC n=descending D. Research Support ONGOING (Co-PI: Stidham R and Waljee A) 10/01/ /30/2019 Department of Defense Peer Reviewed Medical Investigator Initiated Research Award

5 Machine Learning Analysis of Longitudinal Laboratory and Imaging Data to Personalize the Prediction of Severe Complications in Veterans With Crohn s Disease The goal of this study is to use analytic morphomic image analysis with longitudinal laboratory data to yield personalized predictions of future complications in Veterans with Crohn s disease. Role: Co-I Pilot Grant UM-Peking University Joint Institute PI: Lok, ASF 05/01/ /30/2018 University of Michigan-Peking University Joint Institute for Clinical and Translational Research Role of Visceral Adiposity in the Pathogenesis of Non-Alcoholic Fatty Liver Disease in Lean versus Obese Patients: A Comparative Study between Patients at UMHS versus PUHSC This is a prospective observational study, IRB approval will be obtained from both UMHS and PUHSC before enrollment. Our primary goal is to understand the pathogenesis of NAFLD in lean Chinese. We will be prospectively collecting dietary questionaires, anthropometric measurements and morphomic measurements. Role: Co-Investigator K23 PI: Stidham, R 07/01/ /30/2019 National Institute of Health Improving Prediction of Medical Responsiveness and Clinical Outcomes in Crohn's Disease This is a career development grant for Dr. Stidham. The goal of this proposal is to develop therapeutic decision support tools for Crohn s disease management using quantitative imaging features (analytic morphomics) and novel blood biomarkers to predict probabilities of immediate medical responsiveness and future surgical bowel resection. Role: Collaborator (0% effort,) K01 PI- Zhang 07/01/ /31/2019 National Institute of Health Developing Personalized Treatment for Diabetes Through Novel Imaging Methods This is a career development grant to expand upon the candidate s preliminary work to determine individual differences in terms of analytic morphomics for type 2 diabetes mellitus. Role: Co-Mentor HX , VA HSR&D PI: Waljee, Akbar 2017/1/1 2021/12/31 Advanced Prediction Models to Optimize Treatment and Access for Veterans With Hepatitis C The purpose of this study is to lay the groundwork for risk-based treatment of CHC among non- cirrhotic Veterans in the Veterans Health Administration (VHA) by: (1) developing accurate, clinically relevant, and implementable risk prediction models; (2) engaging Veterans to develop consensus on how to implement riskbased treatment; and (3) evaluating the clinical and economic effects of risk-based treatment. Role: Co-Investigator Completed AGA-Covidien Res. & Dev. Pilot Award in Tech PI: Kown, R 07/01/ /30/2016 American Gastroenterology Research Foundation NCTX Analytic Morphomics in the Study of Pancreatic Cysts The goal of this proposal is to improve the diagnostic accuracy of distinguishing mucinous and non-mucinous cysts on cross-sectional imaging using analytic morphomics. Using this novel methodology, we plan to extract and quantitatively assess the morphology of pancreatic cysts and link these findings to clinical outcomes. Role: Mentor PI: Rongey, UCSF 10/01/ /30/2016 Department of Veterans Affairs/Health Services Research and Development Service Quality Enhancement Research Initiative (QUERI) Program Leveraging HIT to improve specialty care access and coordination in HCV

6 The goal of this proposal will evaluate SCAN-ECHO program s effects on HCV care, the local level factors that facilitate the program s early sustainability and understand the subsequent funding needed to ensure this program s sustainability. Role: Co-investigator